News

The FORTIS-M Phase III trial is investigating Talactoferrin plus best supportive care compared to placebo plus best supportive care in patients with non-small cell lung cancer (NSCLC) whose

The tie up allows Envoy to use MBL’s RIP-Chip technology for its drug discovery and development purpose. Under the agreement, Envoy is responsible to pay an upfront payment,

Seattle Genetics entered into this collaboration with Millennium in April 2009, at which time Millennium has obtained an exclusive ADC license to an initial antigen expressed on solid

Patient enrollment is expected to be completed in the first half of 2011 and the company expects to report top-line results before year end. Unigene is developing its

The safety profile of Ruxolitinib was consistent with previous studies. Incyte said that the randomised, open-label Phase III evaluated Ruxolitinib verus best available therapy in 219 patients with

The company expects to commence the construction by the end of this year. The new plant will feature research, development, and technical service resources In addition to catalyst

Cevira delivers a light-activated treatment known as photodynamic therapy to destroy tissue infections caused by HPV and treat precancerous lesions on the cervix without affecting healthy tissue. Cevira

Anavex will evaluate the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics in the Phase I trial. Anavex-2-73 represents a new class of wholly owned compounds that act through

HinsBet showed identical results compared to the Novo Nordisk‘s products giving local tolerance and absence of pain at the injection site. The inter-patient variability on glycemic control with